BioCentury
ARTICLE | Regulation

A dose of innovation

Does FDA have more appetite for innovation in dose-finding trials than companies do?

August 4, 2017 9:53 PM UTC

A recent workshop to discuss dose-finding strategies for cancer immunotherapy combinations suggests FDA may have more appetite for innovative methods than companies do -- at least for now.

FDA and the American Association for Cancer Research (AACR) co-hosted the July 20 meeting to discuss dose finding and optimization of immunotherapy combination regimens...